霍奇金淋巴瘤诊治进展  

Development of diagnosis and treatment for Hodgkin's lymphoma

作　　者：罗颖婉[1] 佟红艳[1] 

机构地区：[1]浙江大学附属第一医院血液科,杭州310003

出　　处：《中国实用内科杂志》2015年第2期89-95,共7页Chinese Journal of Practical Internal Medicine

基　　金：国家自然科学基金(30870914;81270582;81470290);浙江省自然科学基金杰出青年项目(LR12H08001);浙江省科技厅重大项目(2013c03043-2);浙江省卫生厅支撑学科项目(201234445;2012ZDA013);浙江省中医药局(2012ZA071);卫生部公益性行业科研专项经费项目(201202017)

摘　　要：霍奇金淋巴瘤(Hodgkin’s lymphoma,HL)是一种治愈率较高的恶性淋巴瘤。目前各研究组织提出的分期分级标准对风险调整治疗策略有重要的指导意义。近年来也不断推出低毒有效的联合化疗方案、正电子发射计算机断层扫描(PET)引导的放射治疗和靶向治疗药物。文章综述了HL的临床特征、鉴别诊断、经典型HL早期、进展期、复发难治阶段以及结节性淋巴细胞为主型HL的治疗进展,并强调关注各治疗阶段风险评估的重要性。Hodgkin＇s lymphoma（HL）is a kind of highly curable malignant lymphoma.Staging criteria and risk stratifications from different organizations throughout the world are instructive for risk-adapted therapy.Scientific investigations over the recent years have provided insights into the low toxic and effective chemotherapy, positron emission tomography（PET）-based radiotherapy and new targeted drugs.This review demonstrates the clinical manifestations and differential diagnosis of HL, and the management of HL in the early-stage disease, advanced-stage disease, and at relapse,with a focus on the risk evaluation in each stage.

关 键 词：霍奇金淋巴瘤 预后评价 低毒联合化疗 

分 类 号：R551.2[医药卫生—血液循环系统疾病]